🇺🇸 FDA
Pipeline program

CTX001

VX18-CTX001-131

Phase 3 mab active

Quick answer

CTX001 for Beta-Thalassemia is a Phase 3 program (mab) at CRISPR Therapeutics AG with 3 ClinicalTrials.gov record(s).

Program details

Company
CRISPR Therapeutics AG
Indication
Beta-Thalassemia
Phase
Phase 3
Modality
mab
Status
active

Clinical trials